ADAMTS9

Across TCGA pan-cancer cohorts, ADAMTS9 Mutation is linked to patient survival in 14 of 34 cancer types, making it a survival-associated ADAMTS9 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ADAMTS9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADAMTS9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and OV show a favorable association.

ACC, BRCA, and LUAD are the cancer types where ADAMTS9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
BRCA	OS	Median	II,III,IV	0.697	0.959	<.001	28	view →
LUAD	OS	Median	III,IV	0.163	0.690	<.001	21	view →
UCEC	DFS	Median	All	0.817	0.624	.023	20	view →
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
OV	DFS	Median	All	0.770	0.372	.010	16	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
READ	DFS	Median	All	0.162	0.720	.019	6	view →
PRAD	DFS	Median	All	0.162	0.777	<.001	6	view →
LGG	DFS	Median	All	0.570	0.833	.028	4	view →
HNSC	DFS	Median	II,III,IV	1.000	0.677	.029	3	view →
LIHC	OS	Median	III,IV	0.094	0.615	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

ADAMTS9–ACC (OS)

Open the ACC breakdown →